Insulin human: adverse event reports filed with FDA

3,418

reports as suspect product

0% of all reports · about 153 a year

186

reports, 12 months to June 2026

301 in the 12 months before

70.9%

marked serious by the reporter

56.4% across the class

6.8%

record death among outcomes, as reported

232 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Insulin human reports recording the termmedian drug in insulin

1. Blood glucose increasedraised blood sugar reading25.6%874
2. Hypoglycaemialow blood sugar10.1%345
3. Blood glucose decreasedlow blood sugar reading8.5%291
4. Drug ineffectivethe medicine did not work as expected7.5%258
5. Wrong technique in product usage processthe product was used in the wrong way6.4%220
6. Hyperglycaemiahigh blood sugar5.7%194
7. Incorrect dose administeredthe wrong dose was given4.5%153
8. Headachehead pain3.8%131
9. Maternal exposure during pregnancythe mother took the medicine during pregnancy3.8%131
10. Weight decreasedweight loss3.4%115
11. Wrong technique in drug usage processthe medicine was used in the wrong way3.2%111
12. Glycosylated haemoglobin increaseda raised HbA1c, the long-term sugar measure3.1%105
13. Foetal exposure during pregnancythe unborn baby was exposed to the medicine2.9%98
14. Visual impairmentreduced vision2.8%96
15. Blood glucose abnormal2.8%95
16. Neuropathy peripheralnerve damage in hands or feet2.7%93
17. Falla fall2.6%89
18. Hypertensionhigh blood pressure2.6%88
19. Chest painchest pain2.5%86
20. Diarrhoealoose or frequent stools2.5%84
21. Off label useused for a purpose or in a way not on the label2.4%81
22. Malaisegeneral feeling of being unwell2.3%78
23. Eye haemorrhage2.3%77
24. Cerebrovascular accidentstroke2.2%76
25. Arthritis2.2%75
26. Medication errora mistake in prescribing, dispensing or taking a medicine2.2%75
27. Diabetes mellitus inadequate controldiabetes not well controlled2.2%74
28. Drug dose omissiona dose was missed2.1%72
29. Dizzinesslight-headedness or unsteadiness2%68
30. Cardiac failure congestivecongestive heart failure2%67

Top 30 of 628 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 9 drugs in the insulin class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 36,121 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 47.3% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,418 reports.

Drugs most often listed in the same reports

Other products listed in reports where Insulin human is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the insulin class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Insulin human as a suspect or interacting product; reports listing it only as a concomitant medication (4,269) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.